Source: centralcharts

Press Release: Foghorn Therapeutics : Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class

Read full article »
Foghorn Therapeutics's Competitors | Foghorn Therapeutics's News | Foghorn Therapeutics's Financials
Stay up-to-date with the latest news on Foghorn Therapeutics
Annual Revenue
$5.0-25M
Employees
100-250
Adrian Gottschalk's photo - President & CEO of Foghorn Therapeutics

President & CEO

Adrian Gottschalk

CEO Approval Rating

80/100

Read more
Stay up-to-date with the latest news on Foghorn Therapeutics